Drug Trial Radar · NCT07797335
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,778
Planned (sponsor's estimate)
Start
Aug 24, 2026
Primary completion
Jul 31, 2028
Study completion Sep 20, 2028
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Sep 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.
Conditions
- Type 2 Diabetes
- Cardiovascular Risk
Interventions
ZenagamtideDrug
Zenagamtide will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm (administration to the same body part throughout the study).
Insulin glargine U-100Drug
Insulin glargine U-100 will be administered subcutaneously using SoloSTAR pen-injector to one of the body parts: thigh, abdomen or upper arm (rotation of the injection site within body parts).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Non-inferiority of zenagamtide versus insulin glargine: change in haemoglobin A1c (HbA1c)Time frame: From baseline (week 0) to week 52
Locations
330 sites in 16 countries. Site status is shown where the registry gives one.
Univ of Alabama Birmingham
Birmingham, Alabama · Not yet recruiting
Eastern Shore Rsrch Inst, LLC
Fairhope, Alabama · Recruiting
Chambliss Clinical Trials, LLC
Montgomery, Alabama · Recruiting
Honor Health
Scottsdale, Arizona · Not yet recruiting
First Valley Medical Group
Lancaster, California · Recruiting
Headlands Research CTR Lincoln
Lincoln, California · Recruiting
Torrance Clin Res Inst, Inc.
Lomita, California · Recruiting
Pacific Clinical Studies
Los Alamitos, California · Recruiting
VAGLAHS Clinical Research Center (CRC)
Los Angeles, California · Not yet recruiting
Valley Clinical Trials, Inc.
Northridge, California · Recruiting
Paradigm Clinical Research
San Diego, California · Recruiting
N America Res Inst - San Dimas
San Dimas, California · Recruiting
Encompass Clinical Research_Spring Valley
Spring Valley, California · Recruiting
Innovative Research of W FL
Clearwater, Florida · Recruiting
Nature Coast Clin Rsrch_Crystal River
Crystal River, Florida · Not yet recruiting
Florida Premier Cardiology
Delray Beach, Florida · Not yet recruiting
Encore Medical Research LLC
Hollywood, Florida · Recruiting
East Coast Institute For Research
Jacksonville, Florida · Not yet recruiting
Jacksonville Ctr for Clin Res
Jacksonville, Florida · Not yet recruiting
Clinical Research of Cent FL
Lakeland, Florida · Recruiting
Life Spring Research Foundation LLC
Miami, Florida · Recruiting
Optimus U, Corp
Miami, Florida · Not yet recruiting
Flourish Research - North Miami
Miami, Florida · Not yet recruiting
Inpatient Research Clinic LLC
Miami Lakes, Florida · Not yet recruiting
San Marcus Res Clin Miami Lakes
Miami Lakes, Florida · Recruiting
Trujillo Medical Centers
Miramar, Florida · Recruiting
Suncoast Clinical Research, Inc.
New Port Richey, Florida · Not yet recruiting
Ocala Cardiovascular Research
Ocala, Florida · Recruiting
Suncoast Clinical Research, Inc.
Palm Harbor, Florida · Not yet recruiting
Suncoast Research Associates LLC
Pembroke Pines, Florida · Not yet recruiting
St Johns Center for Clin. Res
Saint Augustine, Florida · Recruiting
Javara/Privia Med Grp GA,LLC
Albany, Georgia · Recruiting
David Kavtaradze MD, Inc.
Cordele, Georgia · Not yet recruiting
Atlanta Heart Specialist
Tucker, Georgia · Not yet recruiting
Rocky Mountain Diab&Osteo Ctr
Idaho Falls, Idaho · Recruiting
Elevate Clinical Research
Gurnee, Illinois · Recruiting
Chicago Medical Research LLC
Hazel Crest, Illinois · Recruiting
Genesis Orthopedics & Sports Medicine
Oak Brook, Illinois · Not yet recruiting
Methodist Medical Center of Illinois
Peoria, Illinois · Not yet recruiting
American Health Network of IN LLC_Franklin
Franklin, Indiana · Not yet recruiting
Showing 40 of 330 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.